Basic medical-insurance questions in China cannot be answered from a national benefits label alone. The result depends on the insured person's participation and contribution record, pooling locality, designated provider, diagnosis and treatment, drug or consumable, payment method, local catalogue and the reason a claim was paid, reduced or refused.
Preserve enrolment and contribution records, the medical-insurance electronic credential, referral or out-of-area filings, prescriptions, medical records, itemized bills, settlement statements, catalogue and price codes, provider agreement, audit extracts, notices and appeal deadlines. Patients, employers, providers and suppliers should separate entitlement disputes from suspected misuse of the medical-insurance fund.
Subject to editorial and legal review. Benefits and procedures are locally implemented and change frequently. Confirm the current rule with the medical-security authority or agency for the relevant pooling area.
Identify the insurance and locality
Confirm whether the person participates in employee basic medical insurance or resident basic medical insurance, the pooling area, contribution status, benefit waiting period and any supplementary coverage. Employer enrolment and contribution failures may require correction and can create employment or social-insurance exposure distinct from the reimbursement claim.
Map the service to the payment rules
Identify the designated medical institution or pharmacy, diagnosis, inpatient or outpatient status, drug, consumable, service item and applicable national and local codes. Check catalogue inclusion, payment limitations, deductible, reimbursement ratio, ceiling, patient co-payment and exclusions. Inclusion in a national catalogue does not by itself establish the amount payable for every patient or use.
Referral, direct settlement and cross-region care
For treatment outside the pooling area, check referral, registration and direct-settlement requirements before care where possible. Preserve confirmation of the filing and the settlement result. If direct settlement fails, ask whether manual reimbursement is available and obtain a complete list of original documents and the submission deadline.
Designated-provider and pharmacy obligations
Designated institutions operate under statute, regulation, policy and a service agreement with the medical-insurance agency. They must provide reasonable and necessary services, verify identity, use correct codes, transmit complete and accurate data, retain records, execute price and payment rules, and cooperate with audits. Internal controls should connect clinical documentation, charging, coding, procurement and claims data.
Payment reform and supplier implications
Diagnosis-related group, diagnosis-intervention packet and other prospective payment methods change provider incentives but do not authorize undertreatment, cost shifting or false coding. Pharmaceutical and device suppliers should distinguish market authorization, procurement, price and medical-insurance payment. Contract forecasts must not assume reimbursement merely because a product may be lawfully sold.
Fund-use audits and investigations
Risk indicators include fabricated services, identity misuse, decomposition of admissions, excessive treatment, duplicate charging, mismatched records, false prescriptions and improper resale. On audit, preserve source records and data lineage, define the sample and legal basis, reconcile clinical and billing evidence, and respond accurately by the stated deadline. Do not rewrite records or pressure patients or staff.
Adverse decisions and remedies
Obtain the written reason for refusal, recovery, suspension or other action and identify whether it is a service-agreement measure or an administrative act. Depending on the decision, routes may include agency review, coordination by the medical-security department, administrative reconsideration or administrative litigation. Contractual and employment issues may proceed separately. Calendar every deadline from the actual notice.
2026 supervision rules
The NHSA implementation rules effective April 1, 2026 strengthen full-process intelligent supervision, clarify agency review and designated-institution duties, address enforcement of service agreements and coordinate cross-region oversight. Providers should test whether policies, permissions, coding controls and audit trails work in practice, including drug and consumable traceability codes.
Working-file checklist
- Insurance type, pooling locality and contribution history.
- Provider designation, referral and out-of-area filing.
- Diagnosis, prescriptions, records and itemized invoices.
- Catalogue, code, price and payment-rule version.
- Settlement statement and written refusal or recovery reason.
- Provider agreement, claims data and audit methodology.
- Notices, communications and remedy deadlines.
Official sources
- Regulations on Supervision and Administration of Medical Security Fund Use
- 2025 national basic medical-insurance medicines catalogue notice
- 2025 catalogue-adjustment framework
- NHSA 2026 fund-supervision priorities
Law checked: September 12, 2026. Official Chinese texts and current local implementation control.
